Quinta de S. Pedro, • Sete Casas • 2674-506 • Loures • Portugal

Hovione

Hovione divestment marks its commitment to supplying highly specialized APIs

By Hovione ·

Portuguese company exits the large volume business of contrast media to concentrate on its CDMO business.

Hovione has concluded the sale of all of the share capital of iMAX Diagnostic Imaging Holding Limited. For Hovione, this sale marks the end of 24 years of history of reliable and uninterrupted supply of iopamidol and iohexol API to the generic industry globally.

Hovione divestment marks its commitment to supplying highly specialized APIs

Hovione entered the generic contrast media business in 1993 and in 2007 moved most of its manufacture to the iMAX factory in China because its capacity in Europe was no longer able to meet clients’ demand. This business continued to show a steady profitable growth and for most of that period represented the largest tonnage of Hovione’s product portfolio. Over the course of these 20 years formulations containing Hovione’s contrast media have been supplied to the growing markets of Asia and have included Japan’s best selling generic medicine.

Faced with considerable opportunities in both the contrast agents business and all its other segments, Hovione decided to focus on its CDMO business, on its off-patent business supplying highly specialized APIs and to exit the large volume business of contrast media. The very significant expansion plans that Hovione has embarked upon since 2016 require all of our attention.

“Getting into iopamidol and iohexol was a decision we took in 1993. Today Hovione’s strategy focuses on difficult-to-make and difficult-to-formulate products, supplied to demanding markets, serving innovative clients. Our contrast media business is growing and has many loyal clients that demand high quality, but it increasingly does not seem a good fit with the rest of our activities. The opportunity to sell iMAX with its manufacturing business of APIs and formulated product to a market leader makes sure this business can continue to develop even better. We are convinced that the buyer will be good owner and employer, and will continue supplying reliably the great clients that have supported iMAX’s growth.” said Guy Villax, CEO.

Read More


Go to company page 

Categories

Market News

Other news in “Market News”

Collaboration facilitates continuous manufacturing

Collaboration facilitates continuous manufacturing 

14 Jun 2018
Recipharm expands inhalation capabilities with acquisition of Sanofi CMO business located in UK

Recipharm expands inhalation capabilities with acquisition of Sanofi CMO business located in UK 

13 Jun 2018
Extended co-operation agreement to benefit Sartorius customers

Extended co-operation agreement to benefit Sartorius customers 

12 Jun 2018